20 completed, 3 terminated, 2 active not recruiting, 2 unknown. 27 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 20, Terminated 3, Active not recruiting 2, Unknown 2 |
| Phase 2 | 16 | Completed 9, Terminated 3, Active not recruiting 2, Unknown 2 |
Follow Dacarbazine: new trials by email Literature Review of Dacarbazine trials Research Report on Dacarbazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Unesbulin, Dacarbazine - Leiomyosarcoma | Phase 1 | Completed | PTC Therapeutics | 41 | 2019-03-13 | 2024-03-15 |
| Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma Dacarbazine, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Classical Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | University of Washington | 50 | 2019-01-09 | 2025-08-05 |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Disease | Phase 1 / Phase 2 | Active not recruiting | Takeda | 59 | 2017-09-06 | 2025-11-10 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) doxorubicin, Bleomycin, vinblastine - Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 82 | 2017-01-25 | 2026-02-17 |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC - Metastatic Melanoma Stage IV | Phase 1 / Phase 2 | Unknown | Philogen S.p.A. | 96 | 2013-07-31 | 2022-04-14 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Brentuximab Vedotin, Dacarbazine, Doxorubicin Hydrochloride - AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2013-03-08 | 2025-08-15 |
| Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus - Advanced Melanoma | Phase 1 / Phase 2 | Unknown | University of Regensburg | 136 | 2012-05-01 | 2012-06-07 |
| E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma Lenvatinib, Dacarbazine - Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Eisai Inc. | 97 | 2010-04-01 | 2016-10-10 |
| Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients Doxorubicine, DTIC, Lenalidomide - Hodgkin Lymphoma | Phase 1 | Completed | University of Cologne | 30 | 2010-04-01 | 2018-03-22 |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma brentuximab vedotin, doxorubicin, vinblastine - Disease, Hodgkin | Phase 1 | Completed | Seagen Inc. | 51 | 2010-01-01 | 2014-12-18 |
| Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine Ipilimumab, Carboplatin, Paclitaxel - Advanced Melanoma | Phase 1 | Completed | Bristol-Myers Squibb | 72 | 2009-02-01 | 2014-01-06 |
| Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma Decitabine, Temozolomide, biopsy - Malignant Melanoma | Phase 1 / Phase 2 | Completed | Hussein Tawbi | 39 | 2008-06-01 | 2017-10-03 |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) AZD6244, Dacarbazine, Erlotinib - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | AstraZeneca | 140 | 2007-12-14 | 2026-05-27 |
| A Phase I/II Study of Dasatinib and Dacarbazine Dasatinib and Dacarbazine (DTIC) - Metastatic Melanoma | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 50 | 2007-11-01 | 2013-12-16 |
| Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers recombinant interferon alfa-2b, cisplatin, sodium stibogluconate - Stage IV Melanoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 22 | 2007-05-01 | 2020-07-24 |
| A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine - Melanoma Neoplasms | Phase 1 | Completed | AstraZeneca | 40 | 2007-01-01 | 2009-05-15 |
| PTK/ZK in Disseminated Malignant Melanoma PTK787/ZK 222584, Dacarbazine - Melanoma | Phase 1 / Phase 2 | Terminated | Michael Weichenthal | 9 | 2006-12-01 | 2021-10-06 |
| A Phase I/II Study of Sunitinib and Dacarbazine Sunitinib, Dacarbazine - Melanoma | Phase 1 / Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 11 | 2006-09-01 | 2011-02-23 |
| A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine Genasense® (G3139, oblimersen sodium), Genasense followed by DTIC; then DTIC alone, DTIC alone; then Genasense followed by DTIC - Advanced Melanoma | Phase 1 | Completed | Genta Incorporated | 2006-04-01 | 2012-03-13 |
Showing 20 of 27. Sign in to see all of them.
Melanoma (13) · Hodgkin Disease (5) · Sarcoma (3) · Leiomyosarcoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Astrocytoma (1) · Bone Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Medullary (1) · Chondrosarcoma (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Colonic Neoplasms (1)
AstraZeneca (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (2) · AmpliMed Corporation (1) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · Centocor, Inc. (1) · Eisai Inc. (1) · Genta Incorporated (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Hussein Tawbi (1) · Istituto Superiore di Sanità (1) · Memorial Sloan Kettering Cancer Center (1) · Michael Weichenthal (1) · National Cancer Institute (NCI) (1)
United States (20) · Germany (6) · Italy (5) · United Kingdom (4) · Canada (3) · Spain (2) · Brazil (1) · France (1) · Japan (1)
Adil Daud, M.D. (2) · Agop Y. Bedikian, MD (1) · Alba Rubio (1) · Albrecht Reichle, Professor (1) · Alison Moskowitz, MD (1) · Andreas Engert, Prof. (1) · Andrew Poklepovic, MD (1) · Antonio Casado (1) · Burton L. Eisenberg, MD (1) · Claudia Valverde (1)
PMID 20564083, PMID 22972589, PMID 24239220, PMID 25086465, PMID 28264648, PMID 28424891, PMID 29280762, PMID 31401903, PMID 32596842, PMID 33203665, PMID 36913694, PMID 37532416, PMID 38684039, PMID 39356980, PMID 39661923, PMID 41836677
2004 (1), 2014 (1), 2015 (1), 2023 (1), UM1CA121947 (1)